Related references
Note: Only part of the references are listed.Clinical Predictors of Relapse after Treatment of Primary Gastrointestinal Cytomegalovirus Disease in Solid Organ Transplant Recipients
A. J. Eid et al.
AMERICAN JOURNAL OF TRANSPLANTATION (2010)
The Efficacy and Safety of 200 Days Valganciclovir Cytomegalovirus Prophylaxis in High-Risk Kidney Transplant Recipients
A. Humar et al.
AMERICAN JOURNAL OF TRANSPLANTATION (2010)
Immune-based therapies for cytomegalovirus infection
Raymund R. Razonable
IMMUNOTHERAPY (2010)
A prospective longitudinal analysis of cytomegalovirus (CMV)-specific CD4+and CD8+T cells in kidney allograft recipients at risk of CMV infection
Albert J. Eid et al.
TRANSPLANT INTERNATIONAL (2010)
International Consensus Guidelines on the Management of Cytomegalovirus in Solid Organ Transplantation
Camille N. Kotton et al.
TRANSPLANTATION (2010)
Valganciclovir Dosing According to Body Surface Area and Renal Function in Pediatric Solid Organ Transplant Recipients
W. Vaudry et al.
AMERICAN JOURNAL OF TRANSPLANTATION (2009)
Cytomegalovirus in Solid Organ Transplant Recipients
A. Humar et al.
AMERICAN JOURNAL OF TRANSPLANTATION (2009)
An Assessment of Herpesvirus Co-infections in Patients with CMV Disease: Correlation with Clinical and Virologic Outcomes
A. Humar et al.
AMERICAN JOURNAL OF TRANSPLANTATION (2009)
Interlaboratory Comparison of Cytomegalovirus Viral Load Assays
X. L. Pang et al.
AMERICAN JOURNAL OF TRANSPLANTATION (2009)
Cell-Mediated Immunity to Predict Cytomegalovirus Disease in High-Risk Solid Organ Transplant Recipients
D. Kumar et al.
AMERICAN JOURNAL OF TRANSPLANTATION (2009)
The R753Q Polymorphism Abrogates Toll-Like Receptor 2 Signaling in Response to Human Cytomegalovirus
Robert A. Brown et al.
CLINICAL INFECTIOUS DISEASES (2009)
Long-term outcomes of cytomegalovirus infection and disease after lung or heart-lung transplantation with a delayed ganciclovir regimen
Lora D. Thomas et al.
CLINICAL TRANSPLANTATION (2009)
An Assessment of Donor-to-Recipient Transmission Patterns of Human Cytomegalovirus by Analysis of Viral Genomic Variants
Oriol Manuel et al.
JOURNAL OF INFECTIOUS DISEASES (2009)
Vaccine Prevention of Maternal Cytomegalovirus Infection
Robert F. Pass et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Kinetics of interferon-gamma producing cytomegalovirus (CMV)-specific CD4+and CD8+T lymphocytes and the risk of subsequent CMV viremia after allogeneic hematopoietic stem cell transplantation
A. J. Eid et al.
TRANSPLANT INFECTIOUS DISEASE (2009)
Deficiency of cytomegalovirus (CMV)-specific CD8+ T cells in patients presenting with late-onset CMV disease several years after transplantation
N. W. Cummins et al.
TRANSPLANT INFECTIOUS DISEASE (2009)
Improvement in long-term renal graft survival due to CMV prophylaxis with oral ganciclovir: Results of a randomized clinical trial
V. Kliem et al.
AMERICAN JOURNAL OF TRANSPLANTATION (2008)
Delayed-onset primary cytomegalovirus disease and the risk of allograft failure and mortality after kidney transplantation
Supha K. Arthurs et al.
CLINICAL INFECTIOUS DISEASES (2008)
Human cytomegalovirus load measurement and its applications for pre-emptive therapy in patients undergoing hematopoietic stem cell transplantation
Fausto Baldanti et al.
HEMATOLOGICAL ONCOLOGY (2008)
Cytomegalovirus UL97 mutations in the era of ganciclovir and maribavir
Sunwen Chou
REVIEWS IN MEDICAL VIROLOGY (2008)
Clinical features and outcomes of cytomegalovirus retinitis after transplantation
A. J. Eid et al.
TRANSPLANT INFECTIOUS DISEASE (2008)
Emergence of drug-resistant cytomegalovirus in the era of valganciclovir prophylaxis: therapeutic implications and outcomes
Albert J. Eid et al.
CLINICAL TRANSPLANTATION (2008)
Cytomegalovirus infection and new-onset post-transplant diabetes mellitus
En-Ling Leung Ki et al.
CLINICAL TRANSPLANTATION (2008)
Establishing pharmacokinetic bioequivalence of valganciclovir oral solution versus the tablet formulation
M. D. Pescovitz et al.
TRANSPLANTATION PROCEEDINGS (2007)
Delayed-onset primary cytomegalovirus disease after liver transplantation
Supha K. Arthurs et al.
LIVER TRANSPLANTATION (2007)
Cytomegalovirus disease in solid organ transplant recipients: advances lead to new challenges and opportunities
Albert J. Eid et al.
CURRENT OPINION IN ORGAN TRANSPLANTATION (2007)
Clinical features and outcomes of delayed-onset primary cytomegalovirus disease in cardiac transplant recipients
Supha Kijpittayarit-Arthurs et al.
JOURNAL OF HEART AND LUNG TRANSPLANTATION (2007)
The use of sirolimus in ganciclovir-resistant cytomegalovirus infections in renal transplant recipients
Kikumi Suzete Ozaki et al.
CLINICAL TRANSPLANTATION (2007)
Oral valganciclovir is noninferior to intravenous ganciclovir for the treatment of cytomegalovirus disease in solid organ transplant recipients
A. Asberg et al.
AMERICAN JOURNAL OF TRANSPLANTATION (2007)
Incidence and clinical features of ganciclovir-resistant cytomegalovirus disease in heart transplant recipients
Fanny Li et al.
CLINICAL INFECTIOUS DISEASES (2007)
Active CMV disease does not always correlate with viral load detection
J. Ruell et al.
BONE MARROW TRANSPLANTATION (2007)
The influence of innate immunity gene receptors polymorphisms in renal transplant infections
Carlos Cervera et al.
TRANSPLANTATION (2007)
Relationship between toll-like receptor 2 polymorphism and cytomegalovirus disease after liver transplantation
Supha Kijpittayarit et al.
CLINICAL INFECTIOUS DISEASES (2007)
Persistent cytomegalovirus infection in kidney allografts is associated with inferior graft function and survival
Ilkka Helantera et al.
TRANSPLANT INTERNATIONAL (2006)
Preventing post-organ transplantation cytomegalovirus disease with ganciclovir: A meta-analysis comparing prophylactic and preemptive therapies
Lorne N. Small et al.
CLINICAL INFECTIOUS DISEASES (2006)
Prophylactic versus preemptive oral valganciclovir for the management of cytomegalovirus infection in adult renal transplant recipients
J. A. Khoury et al.
AMERICAN JOURNAL OF TRANSPLANTATION (2006)
Acute rejection and cardiac allograft vascular disease is reduced by suppression of subclinical cytomegalovirus infection
Luciano Potena et al.
TRANSPLANTATION (2006)
Impact of cytomegalovirus in organ transplant recipients in the era of antiviral prophylaxis
Ajit P. Limaye et al.
TRANSPLANTATION (2006)
Primary cytomegalovirus disease after five years of antiviral prophylaxis
S Kijpittayarit et al.
TRANSPLANTATION (2006)
Meta-analysis: The efficacy of strategies to prevent organ disease by cytomegalovirus in solid organ transplant recipients
AC Kalil et al.
ANNALS OF INTERNAL MEDICINE (2005)
Herpesvirus infections in solid organ transplant patients at high risk of primary cytomegalovirus disease
RR Razonable et al.
JOURNAL OF INFECTIOUS DISEASES (2005)
Clinical impact of ganciclovir-resistant cytomegalovirus infections in solid organ transplant patients
G Boivin et al.
TRANSPLANT INFECTIOUS DISEASE (2005)
Management of cytomegalovirus infection in lung transplant recipients: Evidence-based recommendations
MR Zamora et al.
TRANSPLANTATION (2005)
A trial of valganciclovir prophylaxis for cytomegalovirus prevention in lung transplant recipients
A Humar et al.
AMERICAN JOURNAL OF TRANSPLANTATION (2005)
Relevance of Toll-like receptor-4 polymorphisms in renal transplantation
D Ducloux et al.
KIDNEY INTERNATIONAL (2005)
Clinical utility of cytomegalovirus (CMV) serology testing in high-risk CMV D+/R- transplant recipients
A Humar et al.
AMERICAN JOURNAL OF TRANSPLANTATION (2005)
Kinetics of cytomegalovirus load decrease in solid-organ transplant recipients after preemptive therapy with valganciclovir
FM Mattes et al.
JOURNAL OF INFECTIOUS DISEASES (2005)
Correlation between viral loads of cytomegalovirus in blood and bronchoalveolar lavage specimens from lung transplant recipients determined by histology and immunohistochemistry
RF Chemaly et al.
JOURNAL OF CLINICAL MICROBIOLOGY (2004)
Efficacy and safety of valganciclovir vs. oral ganciclovir for prevention of cytomegalovirus disease in solid organ transplant recipients
C Paya et al.
AMERICAN JOURNAL OF TRANSPLANTATION (2004)
Clinical utility of cytomegalovirus viral load testing for predicting CMV disease in D+/R- solid organ transplant recipients
A Humar et al.
AMERICAN JOURNAL OF TRANSPLANTATION (2004)
Risk factors for cytomegalovirus viremia and disease developing after prophylaxis in high-risk solid-organ transplant recipients
RB Freeman et al.
TRANSPLANTATION (2004)
Late-onset cytomegalovirus disease in liver transplant recipients despite antiviral prophylaxis
AP Limaye et al.
TRANSPLANTATION (2004)
The clinical impact of ganciclovir prophylaxis on the occurrence of bacteremia in orthotopic liver transplant recipients
LS Munoz-Price et al.
CLINICAL INFECTIOUS DISEASES (2004)
Decreased incidence of cytomegalovirus infection in thymoglobulin-treated transplant patients with 6 months of valganciclovir prophylaxis
E Akalin et al.
AMERICAN JOURNAL OF TRANSPLANTATION (2004)
Following universal prophylaxis with intravenous ganciclovir and cytomegalovirus immune globulin, valganciclovir is safe and effective for prevention of CMV infection following lung transplantation
MR Zamora et al.
AMERICAN JOURNAL OF TRANSPLANTATION (2004)
Everolimus for the prevention of allograft rejection and vasculopathy in cardiac-transplant recipients
HJ Eisen et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
Dynamics of cytomegalovirus replication during preemptive therapy with oral ganciclovir
RR Razonable et al.
JOURNAL OF INFECTIOUS DISEASES (2003)
Human cytomegalovirus pp67 mRNAemia versus pp65 antigenemia for guiding preemptive therapy in heart and lung transplant recipients:: A prospective, randomized, controlled, open-label trial.
G Gerna et al.
TRANSPLANTATION (2003)
The pathogenesis of hepatitis C virus is influenced by cytomegalovirus
RR Razonable et al.
CLINICAL INFECTIOUS DISEASES (2002)
Ganciclovir-resistant cytomegalovirus in organ transplant recipients
AP Limaye
CLINICAL INFECTIOUS DISEASES (2002)
The impact of human herpesvirus-6 and-7 infection on the outcome of liver transplantation
RR Razonable et al.
LIVER TRANSPLANTATION (2002)
Human cytomegalovirus (HCMV) replication dynamics in HCMV-naive and -experienced immunocompromised hosts
VC Emery et al.
JOURNAL OF INFECTIOUS DISEASES (2002)
Definitions of cytomegalovirus infection and disease in transplant recipients
P Ljungman et al.
CLINICAL INFECTIOUS DISEASES (2002)
Impact of cytomegalovirus infection, year of transplantation, and donor age on outcomes after liver transplantation for hepatitis C
KW Burak et al.
LIVER TRANSPLANTATION (2002)
Preemptive use of oral ganciclovir to prevent cytomegalovirus infection in liver transplant patients: A randomized, placebo-controlled trial
CV Paya et al.
JOURNAL OF INFECTIOUS DISEASES (2002)
The clinical use of various blood compartments for cytomegalovirus (CMV) DNA quantitation in transplant recipients with CMV disease
RR Razonable et al.
TRANSPLANTATION (2002)
High incidence of ganciclovir-resistant cytomegalovirus infection among lung transplant recipients receiving preemptive therapy
AP Limaye et al.
JOURNAL OF INFECTIOUS DISEASES (2002)
Role of the laboratory in diagnosis and management of cytomegalovirus infection in hematopoietic stem cell and solid-organ transplant recipients
RR Razonable et al.
JOURNAL OF CLINICAL MICROBIOLOGY (2002)
Comparative quantitation of cytomegalovirus (CMV) DNA in solid organ transplant recipients with CMV infection by using two high-throughput automated systems
RR Razonable et al.
JOURNAL OF CLINICAL MICROBIOLOGY (2001)
Allograft rejection predicts the occurrence of late-onset cytomegalovirus (CMV) disease among CMV-mismatched solid organ transplant patients receiving prophylaxis with oral ganciclovir
RR Razonable et al.
JOURNAL OF INFECTIOUS DISEASES (2001)
Impact of cytomegalovirus hyperimmune globulin on outcome after cardiothoracic transplantation - A comparative study of combined prophylaxis with CMV hyperimmune globulin plus ganciclovir versus ganciclovir alone
HA Valantine et al.
TRANSPLANTATION (2001)
Prospective randomized trial to assess the value of preemptive oral therapy for CMV infection following liver transplantation.
N Rayes et al.
TRANSPLANTATION (2001)
Levels of virus-specific CD4 T cells correlate with cytomegalovirus control and predict virus-induced disease after renal transplantation
M Sester et al.
TRANSPLANTATION (2001)
Human β-herpesvirus interactions in solid organ transplant recipients
JC Mendez et al.
JOURNAL OF INFECTIOUS DISEASES (2001)
Relationship between IgM antibody to human cytomegalovirus, virus load, donor and recipient serostatus, and administration of methylprednisolone as risk factors for cytomegalovirus disease after liver transplantation
VC Emery et al.
JOURNAL OF INFECTIOUS DISEASES (2000)
Valganciclovir results in improved oral absorption of ganciclovir in liver transplant recipients
MD Pescovitz et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2000)
Cytomegalovirus antigenemia directed pre-emptive prophylaxis with oral versus i.v. ganciclovir for the prevention of cytomegalovirus disease in liver transplant recipients - A randomized, controlled trial
N Singh et al.
TRANSPLANTATION (2000)
Prediction of cytomegalovirus load and resistance patterns after antiviral chemotherapy
VC Emery et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2000)
Application of viral-load kinetics to identify patients who develop cytomegalovirus disease after transplantation
VC Emery et al.
LANCET (2000)
Cytomegalovirus (CMV) DNA load predicts relapsing CMV infection after solid organ transplantation
IG Sia et al.
JOURNAL OF INFECTIOUS DISEASES (2000)
An association between cytomegalovirus infection and chronic rejection after liver transplantation
PC Evans et al.
TRANSPLANTATION (2000)